中文

← All funding rounds

Aureka Biotechnologies

Also known as AurekaBio, Aureka

United StatesProtein designLaguna Hills, California, and Shanghai (the release's dateline), United States and ChinaFounded 2023Private

Website · aurekabio.com ↗

Designs antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.

Disclosed total$100M
Rounds on record1
Latest round$100MSeries B · 2026-08-11
Last stated valuationNone stated
Investors named5
Research on record2highest level 4 · Tested in the physical world

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date$100MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Series B, 2026-08-11: the record then held 1 research entry, highest level 2. The first research entry is dated 2026-07-04; the highest level so far is 4 (Tested in the physical world).

Rounds and research, on one timeline

  1. 2026-09-09
    Research

    Level 4 · Tested in the physical world

    Aureka opens up its agentic antibody-design harness, and 38 of 80 designs from it bound their target in the company's own lab

    What is released is the loop, not a model: the gates deciding which part of the target a design must touch, the candidate population and each cycle's written reflection are all in the open repository, so another group can run the same search policy on its own targets. The hit rates come with the molecular format each design was made in, which is what someone reusing it must plan around: against CXCR4, 6 of 20 single-domain designs bound and 4 of 20 full antibodies. Representative affinities are 540 pM for RAGE and 4.5 nM for a CXCR4 single-domain binder.

    Timeline entry →github.com ↗

  2. 2026-08-11Series B
    Round

    $100M

    For: research and large-scale training of its next biological foundation model, and an upgraded Lab-in-the-Loop platform linking the model to its single-cell functional screening and high-throughput validation

    Models and platformWet lab

    Closed in tranches: Granite Asia alone funded the first (as sole investor, not called lead). The company's Chinese release names Qiming among existing investors; the English version (Pulse 2.0) lists MPCi and NRL Capital and leaves Qiming out. Total raised nearly $200M, per the company. Valuation not disclosed.

    Lead · an unnamed industry investor (later tranche)Granite AsiaHighLight CapitalExisting investor · Qiming Venture PartnersExisting investor · Matrix Partners ChinaExisting investor · NRL Capital

    On the deal: Yinghui Kuang (Spoke for the firm in the announcement, Granite Asia)

    By this date the record held 1 research entry, highest level 2

    Announced by the company · hub.baai.ac.cn ↗On the timeline →

  3. 2026-07-04
    Research

    Level 2 · Computed

    Aureka releases OpenDDE, an open co-folding model that predicts an acceptable interface for 66.4% of antibody-antigen complexes on a new test set it curated, against 51.0% for the next best model

    Antibody-antigen interfaces are flexible, hard for co-folding models, and where antibody companies need them most, and the strongest reported system, Isomorphic Labs' IsoDDE, is closed. An open model close to it lets any lab run and retrain the structure step itself. It is also the model under Aureka's agentic design harness, so that harness's lab results rest on it.

    Timeline entry →arxiv.org ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.